Towards personalized medicine in antifungal treatmentcombination of pharmacogenetics and pharmacokinetics

  1. Blanco Dorado, Sara
unter der Leitung von:
  1. M.ª Jesús Lamas Díaz Doktorvater/Doktormutter
  2. Manuel Campos Toimil Doktorvater
  3. Anxo Fernández Ferreiro Doktorvater/Doktormutter

Universität der Verteidigung: Universidade de Santiago de Compostela

Fecha de defensa: 05 von Juni von 2020

Gericht:
  1. Olga Delgado Sánchez Präsident/in
  2. Arturo González Quintela Sekretär
  3. Fernando Gutiérrez Nicolás Vocal
Fachbereiche:
  1. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica

Art: Dissertation

Zusammenfassung

Voriconazole is an antifungal agent used in aspergillosis and in fluconazole-resistant Candida spp. infections. Voriconazol is mainly metabolized by cytochrome 2C19 wich is highly polymorphic. A significant portion of patients fail to achieve therapeutic drug concentrations, with a consequently increased risk of therapeutic failure. In this work, the use of voriconazole in the real life clinical setting was studied and a HPLC method for the pharmacokinetic determination of voriconazole was developed. In addition, the factors of voriconazole pharmacokinetic variability were evaluated demonstrating the importance of CYP2C19 pharmacogenetics and pharmacokinetic drug-drug interactions.